RESUMEN
Objective:To investigate the application value of modified through-suture T-tube in laparoscopic biliary tract surgery.Methods:The retrospective and descriptive study was constructed. The clinical data of 15 patients with cholecystolithiasis and choledocholithiasis who underwent laparoscopic biliary tract surgery in China-Japan Friendship Hospital of Jilin University from January to December 2022 were collected. There were 8 males and 7 females, aged (49± 14)years. Of 15 patients, 8 cases undergoing laparoscopic cholecystectomy + common bile duct exploration and lithotomy+conventional T-tube drainage were set as conventional group and 7 cases undergoing laparoscopic cholecystectomy + common bile duct exploration and lithotomy+modified through-suture T-tube drainage were set as modified group. Observation indicators: (1) intraoperative and postoperative conditions; (2) follow-up. Measurement data with normal distribution were expressed as Mean± SD, and comparison between groups was conducted using the t test. Count data were described as absolute numbers, and comparison between groups was conducted using Fisher exact probability. Results:(1) Intraoperative and postoperative conditions. Both groups of patients successfully completed the operation, with postoperative vital signs as stable, and no discomfort symptoms. There was no significant difference in duration of postoperative hospital stay between the coventional group and the modified group ( P>0.05). (2) Follow-up. Both groups of patients completed 30 days of postoperative outpatient follow-up. There was a significant difference in the sinus wall thickness between the coventional group and the modified group ( P<0.05). Among the 8 patie-nts in the conventional group, T tube was removed in the first 2 cases of patients after T tube angio-graphy 30 days after operation, and biliary fistula occurred in 1 of them and the drainage tube was re-indurated. For the other 6 cases, the time of T tube retention was extended to 6 weeks after surgery. After T tube angiography, the T tube was removed and no biliary fistula occurred. Among the 7 patients in the modified group, 2 cases with residual choledocholithiasis were found by T tube angiography 30 days after operation. After removal of T tube, percutaneous choledochoscopy was performed, in which the sinus wall was well formed and stone removal was smooth. The other 5 pati-ents were confirmed no residual calculi by T-tube angiography, and then the T-tube was removed, with no biliary fistula. Conclusion:Modified through-suture T-tube can be used in laparoscopic biliary tract surgery.
RESUMEN
<p><b>OBJECTIVE</b>To investigate the effect of Cdc42-shRNA plasmid to proliferation, migration, invasion and other malignant biological behavior in hepatoma SMMC-7721 cells.</p><p><b>METHODS</b>Cdc42-shRNA interfering vector transfected to SMMC-7721 cells with liposome method. The growth curve of transfected cells SMMC-7721, U6-control, Cdc42-shRNA2 was detected by MTT. The cells mobility was detected by wound healing experiment. Transwell chamber experiments to observe the cell migration and invasion. Detected AFP and PCNA expression level by Western blot.Human hepatoma SMMC-7721 transplanted subcutaneously in nude mouse, detected the expression of Cdc42 of the tumor by immunohistochemistry.t test was used to analyze the data between two groups.</p><p><b>RESULTS</b>The doubling time of Cdc42-shRNA2, U6-control and SMMC7721 was 42.7 h, 34.9 h and 35.1 h. The relative migration distance of Cdc42-shRNA2 and U6-control on 36 h was (47.1 ± 4.1)% and (86.6 ± 5.3)% (t=-10.21, P<0.05). Transwell chamber experimental methods showed the numbers of permeating cells were 18.2 ± 2.1(Cdc42-shRNA2) and 41.0 ± 3.5 (U6-control) (t=-9.67, P<0.05) on 24 h. The AFP and PCNA expression of hepatoma cells is significantly inhibited after the Cdc42-shRNA2 was transfected compared with U6-control group.The tumor average weight of group Cdc42-shRNA2 was (335.1 ± 178.2) mg, which was much lighter than that of SMMC-7721 group ((925.3 ± 241.4) mg) and U6-control group ((910.5 ± 225.6) mg) (t=-4.47, -4.39; P<0.05) and the Cdc42 expression was also weak positive.</p><p><b>CONCLUSION</b>Cdc42 interfere with plasmid significant changes in human malignant biological behavior of hepatocellular carcinoma cells, and reduces liver cancer cell growth, invasion and metastasis of capacity.</p>